IRBM’s Advent, a global leader in viral vector manufacturing, has made thousands of doses of a novel Covid-19 vaccine, called AZD1222, for use by the University of Oxford and AstraZeneca in clinical trials in the UK, Brazil and South Africa.
We are delighted to see the positive results of initial trials, showing the vaccine produces a strong immune, as reported by The Lancet, one of the world’s oldest and best-known general medical journals. This shows just what science can do when we all work together, taking us one step closer to finding a successful vaccine. You can read the University of Oxford’s press release here.
We are proud to be using our passion for science to continue to support this vital work to help protect people the world over from the deadliest pandemic in a generation.